ERBB2 and breast carcinoma: Cai et al. (2020) in an open-label phase I clinical trial (NCT03546478) involving patients with HER2-positive breast cancer demonstrated specific binding (overall specificity, 60%) of the 99mTc-labeled HER2-targeted affinity ABH2 affibody to target molecules without noticeable adverse effects for the patient.